More than 90% of patients with mastocytosis have a somatic gain-of-function mutation in the KIT receptor tyrosine kinase, primarily an aspartic acid-to-valine substitution (D816V), which results in enhanced survival and cell autonomous growth of neoplastic mast cells (MCs). Here, KIT is linked to mastocytosis.